Detection of dysplastic or neoplastic cells using anti-MCM3 antibodies
Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, esophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.
1. A method of determining the presence or absence of dysplastic or neoplastic cervical cells in a test sample containing cells from an individual, wherein the test sample comprises a cervical cytology sample, the method comprising:
contacting the test sample with an antibody or antibody fragment directed against Minichromosome Maintenance protein 3 (MCM3 protein);
determining the amount and/or pattern of binding of said antibody or antibody fragment to said test sample;
whereby an increase in said amount and/or a difference in said pattern if detected for the test sample compared with a normal sample is indicative of presence of dysplastic or neoplastic cervical cells in said test sample; and
if an increase in said amount and/or a difference in said pattern is detected for the test sample compared with a normal sample, selecting the individual from which the test sample was obtained for a Pap smear test, a human papilloma virus (HPV) test and/or biopsy testing.
2. A method according to claim 1 wherein a population of individuals is screened.
3. A method according to claim 1 wherein the sample is a cervical smear.
4. A method according to claim 3 wherein a population of individuals is screened.